What Abiraterone Treats: Main Uses and Benefits

Abiraterone is used to help manage a specific type of prostate cancer that has spread to other parts of the body. The medication is generally considered relevant for the ongoing management of this condition, specifically metastatic castration-resistant prostate cancer (mCRPC), which means the cancer has progressed despite prior hormone-blocking treatments.

Primary Use in Advanced Prostate Cancer

The key therapeutic use is applied in contexts marked by increased discomfort or tension related to the progression of advanced disease. It is used to help address the overall illness and to manage associated symptoms such as pain, physical discomfort, and persistent fatigue. It contributes to slowing the growth of the condition.

Support for Physical Function and Comfort

By managing the illness and helping to ease key symptoms, the treatment contributes to maintaining a sense of stability when symptoms are more noticeable. This is relevant for managing symptoms that interfere with daily functioning and generally contributes to improved day-to-day comfort and overall quality of life.

---

Quick Fact: Relief for Physical Discomfort

Abiraterone may assist with managing symptoms related to physical discomfort and systemic imbalance often linked to advanced disease, and may help patients cope more steadily with symptom fluctuations.

Regulatory References

1. NIH MedlinePlus overview

Abiraterone eligibility is strictly governed by regulatory documentation, focusing on patient sex, age, and pre-existing medical conditions, and is limited to adult male patients.

Contraindicated Populations

Abiraterone is formally contraindicated in the following groups:

• Women who are or may become pregnant (due to risk of fetal harm).
• Patients with baseline severe hepatic impairment (Child-Pugh Class C).
• Patients with known hypersensitivity to the active substance or any excipients.

Conditional and Restricted Use

Use is restricted or conditional in specific populations:

• Moderate hepatic impairment (Child-Pugh Class B) requires a dose reduction and strict monitoring of liver function.
• Patients with a history of cardiovascular disease (e.g., severe heart failure) require caution, as safety has not been established in those with LVEF < 50% or NYHA Class III/IV heart failure.
• The medicine is not recommended in combination with radium Ra 223 dichloride.

Age-Related Rules

Abiraterone is not indicated for use in the pediatric population as safety and effectiveness have not been established. For older adults (geriatric use), no overall differences in safety or effectiveness have been observed compared to younger patients.

Official Interactions with Other Medicines and Products

Abiraterone's regulatory profile documents several mandatory restrictions and constraints concerning co-administration with other substances and food. These are defined by the drug's metabolic pathway and its influence on other enzyme systems.

Classification	Interacting Entity (Examples)	Interaction Outcome / Constraint
Prohibited Combination	Spironolactone	Contraindicated due to pharmacodynamic interference that may increase PSA levels.
Not Recommended Use	Radium Ra 223 dichloride	Combination with Abiraterone plus prednisone/prednisolone is not recommended outside of clinical trials (increased mortality/fractures).
Metabolic Inhibition	CYP2D6 Substrates CYP2C8 Substrates	Abiraterone is an inhibitor of these enzymes, leading to an increased systemic exposure of co-administered medicines (e.g., Pioglitazone, Repaglinide).
Exposure Reduction	Strong CYP3A4 Inducers (e.g., Rifampin)	Abiraterone is a CYP3A4 substrate. Co-administration decreases Abiraterone exposure by approximately 55%, and should be avoided.
Food Constraint	Food (Meals)	Food significantly increases Abiraterone systemic exposure (up to 10-fold or more). Requires administration on an empty stomach (no food 1 hour before or 2 hours after).

Use is formally prohibited in patients with baseline severe hepatic impairment (Child-Pugh Class C), as stated in regulatory prescribing information.

Abiraterone acetate is a prodrug that is converted in the body to its active form, abiraterone, which works by directly and selectively inhibiting the CYP17A1 enzyme (17alpha-hydroxylase/C17,20-lyase).

Inhibition of Androgen Synthesis Pathways

This mechanistic domain involves blocking the CYP17A1 enzyme across production sites, including the adrenal glands, testes, and tumor tissue, a critical step in the steroidogenesis pathway. This inhibition limits the synthesis of androgens, such as testosterone and dihydrotestosterone (DHT), and contributes to the reduction of androgen-driven signaling in the targeted cells.

Modulation of Steroid Biosynthesis Cascades

The blockade of CYP17A1 causes a subsequent diversion of precursor hormones towards the synthesis of mineralocorticoids (like deoxycorticosterone). This resulting increase in mineralocorticoid activity is a predictable physiological adjustment that may affect electrolyte and fluid balance, which results in the engagement of regulatory feedback mechanisms.

Damping Androgen Receptor Signaling

This final domain explains the downstream consequence of reduced hormone levels. By severely limiting the availability of the ligands (androgens) that activate the Androgen Receptor (AR), Abiraterone contributes to suppressing the signaling sequences essential for cell activity. This action limits the ability of the AR to stimulate gene transcription, thereby resulting in a state of decreased activity within the targeted endocrine-driven growth pathway.

Abiraterone acetate is administered solely by the oral route as film-coated tablets, with administration following specific timing and co-treatment requirements. This medicine is taken alongside a method to maintain the patient's castrate status.

---

Dosing and Administration

The standard daily dose is 1,000 mg taken once daily. This regimen is taken concurrently with the co-administration of a glucocorticoid, typically low-dose prednisone or prednisolone (e.g., 5 mg twice daily), as an integral component of the overall protocol. This once-daily frequency is intended for continuous use until evidence of disease progression.

A critical requirement for administration is the fasting condition, which is essential for ensuring predictable systemic absorption. The tablets must be taken on an empty stomach: this necessitates avoiding food for at least two hours before and one hour after taking the dose. The whole tablet must be swallowed with water and must not be crushed or chewed.

---

Population-Specific Use

Dosing modifications are established for specific patient contexts. For instance, in patients with moderate hepatic impairment (Child-Pugh Class B), the starting dose is reduced to 250 mg once daily. Conversely, no specific dose adjustment is necessary for patients with renal impairment or for older adults. If a dose is missed, the patient should simply skip the missed dose and resume the regular schedule the following day, without taking a double dose.

Research evidence / Overview of studies for Abiraterone

This section provides a summary of the types of research and clinical studies that have been conducted to evaluate Abiraterone. This information describes the structure of the evidence and what was observed in study groups, and should not be used as clinical advice or to predict individual outcomes.

---

Evidence for Use in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

This section summarizes the framework of large, foundational randomized controlled trials (RCTs) and systematic reviews that examined the medicine’s use in patients whose cancer was observed in a castrate-resistant state despite previous hormonal treatment.

Clinical Trials in the Post-Chemotherapy Setting

The initial large RCTs, such as the COU-AA-301 trial, were conducted in men whose cancer progressed after they had already received chemotherapy. In these studies, researchers primarily examined key long-term outcomes, including Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS). These trials also included patient-reported outcome measures of pain and physical discomfort. Findings from these pivotal trials describe patterns related to the length of overall survival when compared to the control group.

Clinical Trials in the Pre-Chemotherapy Setting

Similar large RCTs, including the COU-AA-302 trial, were evaluated in men with mCRPC who had not yet received chemotherapy. This research explored outcomes related to pain and physical discomfort, such as the time until patients needed to start using strong pain medication (opiates), and the time until the initiation of subsequent chemotherapy treatments. Data show patterns related to the observed duration of these outcomes when Abiraterone was studied for this population compared to control groups. These studies contribute to the broader evidence landscape for mCRPC.

---

Evidence for Use in High-Risk Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

This section will describe the structure of the key international clinical trials that investigated Abiraterone when added to standard hormone therapy for men newly diagnosed with metastatic disease that carries high-risk features.

• Large international RCTs, such as the LATITUDE and STAMPEDE trials, were evaluated in men starting initial hormone therapy who had high-risk factors, such as many areas of cancer spread. The primary measurements collected were studied for Overall Survival (OS) and the time until the disease worsened. These studies also monitored the rate of initial response (measured by a drop in PSA levels), the time to the first skeletal-related event, and patient-reported outcomes describing perceived discomfort.
• Research describes measurements of overall survival and time to progression when Abiraterone was studied alongside standard treatment. The evidence describes research conducted in patients with this specific high-risk profile.

---

Long-Term Studies and Follow-up Data

This section synthesizes information from extended follow-up periods of the pivotal trials, explaining what is currently known and what remains uncertain about the durability of the research findings.

• The major clinical trials were studied for long follow-up durations, with final analyses extending for four years or more in some cases, contributing to understanding patterns in overall survival over extended periods.
• While the follow-up durations were limited in the initial reports, the extended data provide further context. However, long-term effects are not fully established regarding the medicine’s potential impact on certain health factors outside of the primary cancer outcomes, as the trials were not specifically designed to measure these elements over a decade or more.

---

Evidence in Specific Patient Groups

This section outlines what studies have evaluated Abiraterone in distinct patient populations, based primarily on the regulatory reviews of clinical trial data.

• Older Adults: The major Phase 3 studies examined older adults, with approximately 70% of participants being 65 years and over. Findings describe group patterns, indicating that these older populations were studied for similar outcomes as younger populations, but results apply only to the populations studied.
• Organ Function Research: Specific research was studied for patients with pre-existing mild liver impairment or severe kidney impairment to understand how the medicine was observed in these contexts. However, patients with pre-existing moderate or severe hepatic impairment were generally excluded from the main efficacy trials. This means data for certain groups remain insufficient when it comes to individuals with more severe organ function limitations.

---

What is Still Uncertain About Abiraterone Evidence

This concluding section summarizes and contextualizes the main research gaps and areas where official sources indicate a need for more research or longer observation.

• Research does not predict whether an individual will respond similarly to the group averages observed in the trials. The study results reflect the specific conditions under which they were conducted during periods of increased symptom activity and the defined characteristics of the populations studied.
• Comparative evidence is lacking from large, controlled trials that directly compare Abiraterone against other advanced hormonal therapies in the mCSPC setting.
• Evidence is limited for long-term cardiac outcomes in patients with significant pre-existing heart conditions, as these patients were observed in some studies to be excluded from the main research groups. Research is ongoing to continue understanding the full, long-term profile of the medicine.

Common questions about Абиратерон (FAQ)

Q: Is Abiraterone a type of chemotherapy?

A: Official information classifies Abiraterone as an Androgen Biosynthesis Inhibitor, meaning it works by blocking the body’s production of male hormones (androgens). It is used as an antineoplastic agent, a type of cancer drug, but it is generally distinguished from conventional cytotoxic chemotherapy.

Q: Why do you have to take Abiraterone with another medicine called prednisone?

A: Regulatory documents state that Abiraterone’s action can lead to an increase in mineralocorticoids, a type of hormone, which may cause side effects like high blood pressure and low potassium. The co-administration of prednisone is specified in official instructions to help mitigate the potential effects of this hormonal activity.

Q: Does Abiraterone cure cancer or just manage it?

A: According to official documentation and clinical studies, Abiraterone is approved for the management and control of advanced prostate cancer. The regulatory information available does not contain evidence or claims regarding a cure for the disease.

Q: How long does a person usually stay on Abiraterone?

A: Official treatment protocols specify that the medication is intended for continuous use once daily. This regimen is generally maintained until the healthcare team observes evidence of the disease progressing.

Q: Are there any foods or drinks that should be avoided while taking Abiraterone?

A: The most important constraint is that the regular formulation must be taken on an empty stomach, specifically avoiding food for 2 hours before and 1 hour after the dose. This practice is followed because food significantly increases how much of the medicine is absorbed. No specific foods or drinks other than the general food requirement are typically listed as forbidden in regulatory warnings.

Q: What is the purpose of the prednisone that is taken with Abiraterone?

A: The prednisone is taken alongside Abiraterone to help manage the potential effects of mineralocorticoid excess caused by the drug. This co-treatment is intended to help control possible side effects like high blood pressure, fluid retention, and low potassium levels.

Q: Is it okay to take Abiraterone if I have high blood pressure?

A: Official warnings state that high blood pressure must be assessed and monitored before and during treatment because the drug itself may cause or worsen hypertension. Caution is advised for patients with a history of cardiovascular disease.

Q: Does Abiraterone affect men's fertility?

A: Official documents advise that male patients who have female partners of reproductive potential should use effective contraception during treatment. This caution is based on research that indicated the medicine has the potential to impair fertility.

Q: Does Abiraterone interact with common pain relievers like ibuprofen?

A: Ibuprofen is not specifically listed as an interaction in regulatory documents. However, official information describes Abiraterone as an inhibitor of certain liver enzymes (CYP2D6 and CYP2C8), and caution is generally advised when taking other medicines or products that are processed by these enzymes.

Q: Is it common to have fatigue or tiredness while on Abiraterone?

A: Yes, regulatory prescribing information lists both fatigue and tiredness as very common adverse reactions observed in clinical trials associated with taking Abiraterone.

Q: Can Abiraterone cause mood changes or depression?

A: According to official drug labeling, depression is listed as an adverse reaction that was observed with a frequency of common or less in clinical studies.

Q: Are there any specific supplements to avoid while on this medication?

A: Official documents caution against the use of strong CYP3A4 inducers (substances that speed up the metabolism of Abiraterone), which includes certain herbal remedies. Official guidance emphasizes that all supplements should be reported to a healthcare provider for review.

Q: How does Abiraterone affect cholesterol levels?

A: Clinical data reported in regulatory sources indicate that hypercholesterolemia (high cholesterol) and hypertriglyceridemia (high triglyceride levels) are common laboratory abnormalities that have been associated with this medicine.

Q: Are there different brand names for the medicine Abiraterone?

A: Yes. The active substance is Abiraterone acetate. While Abiraterone is the generic name, it is available globally under various brand names, such as Zytiga or Yonsa, depending on the country.

Q: What are the signs of liver issues I should be aware of while on the drug?

A: Due to the documented risk of liver injury, official information advises patients to report symptoms that could suggest liver problems. These signs may include yellowing of the skin or eyes (jaundice), dark urine, or the onset of severe nausea or vomiting.

Q: Does Abiraterone affect blood sugar levels?

A: Official documents indicate that the medicine can affect glucose control. Hyperglycemia (high blood sugar) is listed as a common laboratory abnormality, and severe hypoglycemia (low blood sugar) has been reported when taken alongside certain diabetes medicines.

Q: Does Abiraterone cause joint pain or muscle aches?

A: Yes. According to the official prescribing information, arthralgia (joint pain) and muscle discomfort or aches are listed as very common adverse reactions that have been reported by patients during treatment.

Q: Can Abiraterone affect my sleep?

A: Official labeling lists insomnia (difficulty falling or staying asleep) as a reported side effect. Also, nocturia (frequent nighttime urination) is listed as a common side effect, which may potentially affect sleep quality.

Q: What happens if I take more Abiraterone than prescribed?

A: In cases of accidental overdose, official regulatory documents state that treatment should consist of general supportive measures, including monitoring of vital functions, as there is no specific antidote.

Q: Is there a generic version of Abiraterone available?

A: Yes, the active ingredient Abiraterone acetate is available in approved generic formulations. This information is listed in regulatory databases such as the FDA’s Approved Drug Products list.

Q: Does Abiraterone interact with common vitamins?

A: Official patient information advises reporting all vitamins and over-the-counter medicines to a healthcare provider. This is because they must be checked for any potential effects on the medicine’s absorption or how it is processed by the body.

Q: What evidence supports the use of Abiraterone in earlier stages of prostate cancer?

A: Official regulatory approval includes its use in men with newly diagnosed, high-risk metastatic castration-sensitive prostate cancer (mCSPC). This is considered an earlier stage of treatment compared to the castration-resistant setting.

Q: How is the effectiveness of Abiraterone treatment monitored?

A: Effectiveness is monitored through clinical measurements and assessments, which typically include tracking prostate-specific antigen (PSA) levels, using imaging to assess cancer spread, and evaluating the patient’s physical well-being.

Q: How soon after starting treatment might PSA levels change?

A: Clinical study summaries indicate that a measurable reduction in prostate-specific antigen (PSA) levels has been observed within the first three to six months of treatment. However, the timing of an individual response can vary.

Q: What is the risk of bone thinning (osteoporosis) with Abiraterone use?

A: Official documents list fractures as a common side effect in clinical trials. Since the medicine is used with other hormonal therapies, there is a recognized potential for reduced bone density, which can increase the risk of fracture.

Abiraterone acetate tablets must be stored under controlled room temperature conditions, specifically between 20 C and 25 C (68 F to 77 F). The medication can tolerate brief temperature excursions from 15 C to 30 C (59 F to 86 F).

The product must be kept in its original, tightly closed container and protected from moisture and humidity. It is a mandatory requirement to store the tablets out of the sight and reach of children and pets.

Pregnant women or women who may become pregnant must not handle the tablets without protective measures, such as gloves, due to potential risk. Unused or expired Abiraterone tablets must not be disposed of in household trash or poured into wastewater. Proper disposal requires returning the medicine to a pharmacist or a designated drug take-back program for pharmaceutical waste handling.